当前位置：
X-MOL 学术
›
Biol. Cell
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: First insight of the underlying mechanisms
Biology of the Cell ( IF 2.4 ) Pub Date : 2021-09-24 , DOI: 10.1111/boc.202100003 Elsa Hadj Bachir 1 , Charles Poiraud 1, 2 , Sonia Paget 1 , Nicolas Stoup 1 , Soumaya El Moghrabi 1 , Belinda Duchêne 1 , Nathalie Jouy 3 , Antonino Bongiovanni 3 , Meryem Tardivel 3 , Louis-Bastien Weiswald 4, 5 , Marie Vandepeutte 1 , César Beugniez 1, 2 , Fabienne Escande 6 , Emmanuelle Leteurtre 1, 7 , 1 , Laurent Poulain 4, 5 , Chann Lagadec 1 , Pascal Pigny 1 , Nicolas Jonckheere 1 , Florence Renaud 1, 7 , Stephanie Truant 1, 2 , Isabelle Van Seuningen 1 , Audrey Vincent 1
Biology of the Cell ( IF 2.4 ) Pub Date : 2021-09-24 , DOI: 10.1111/boc.202100003 Elsa Hadj Bachir 1 , Charles Poiraud 1, 2 , Sonia Paget 1 , Nicolas Stoup 1 , Soumaya El Moghrabi 1 , Belinda Duchêne 1 , Nathalie Jouy 3 , Antonino Bongiovanni 3 , Meryem Tardivel 3 , Louis-Bastien Weiswald 4, 5 , Marie Vandepeutte 1 , César Beugniez 1, 2 , Fabienne Escande 6 , Emmanuelle Leteurtre 1, 7 , 1 , Laurent Poulain 4, 5 , Chann Lagadec 1 , Pascal Pigny 1 , Nicolas Jonckheere 1 , Florence Renaud 1, 7 , Stephanie Truant 1, 2 , Isabelle Van Seuningen 1 , Audrey Vincent 1
Affiliation
|
Although improvements have been made in the management of pancreatic adenocarcinoma (PDAC) during the past 20 years, the prognosis of this deadly disease remains poor with an overall 5-year survival under 10%. Treatment with FOLFIRINOX, a combined regimen of 5-fluorouracil, irinotecan (SN-38) and oxaliplatin, is nonetheless associated with an excellent initial tumour response and its use has allowed numerous patients to go through surgery while their tumour was initially considered unresectable. These discrepancies between initial tumour response and very low long-term survival are the consequences of rapidly acquired chemoresistance and represent a major therapeutic frontier. To our knowledge, a model of resistance to the combined three drugs has never been described due to the difficulty of modelling the FOLFIRINOX protocol both in vitro and in vivo. Patient-derived tumour organoids (PDO) are the missing link that has long been lacking in the wide range of epithelial cancer models between 2D adherent cultures and in vivo xenografts. In this work we sought to set up a model of PDO with resistance to FOLFIRINOX regimen that we could compare to the paired naive PDO.
中文翻译：
一种新的胰腺癌衍生的对 FOLFIRINOX 的获得性化学抗性的类器官模型：对潜在机制的初步了解
由于难以在体外和体内模拟 FOLFIRINOX 方案，从未描述过对三种药物联合耐药的模型。患者来源的肿瘤类器官 (PDO) 是二维贴壁培养和体内异种移植物之间的广泛上皮癌模型中长期缺乏的缺失环节。在这项工作中，我们试图建立一个对 FOLFIRINOX 方案具有抗性的 PDO 模型，我们可以将其与配对的幼稚 PDO 进行比较。
更新日期：2021-09-24
中文翻译：
一种新的胰腺癌衍生的对 FOLFIRINOX 的获得性化学抗性的类器官模型：对潜在机制的初步了解
由于难以在体外和体内模拟 FOLFIRINOX 方案，从未描述过对三种药物联合耐药的模型。患者来源的肿瘤类器官 (PDO) 是二维贴壁培养和体内异种移植物之间的广泛上皮癌模型中长期缺乏的缺失环节。在这项工作中，我们试图建立一个对 FOLFIRINOX 方案具有抗性的 PDO 模型，我们可以将其与配对的幼稚 PDO 进行比较。
京公网安备 11010802027423号